Accessibility Menu
Innovent Biologics logo

Innovent Biologics(OTC) IVBXF

Market Cap$22.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+307%
5 Year+22%
1 Year-6%
1 Month+20%
$12.84
-10.03%
-1.43Today
Innovent Biologics last closing stock price
MetricPriceDate
Last closeUSD 12.842026-09-03
Innovent Biologics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.6%USD 14.202026-08-27
1 month+20.22%USD 10.682026-08-04
3 month+27.2%USD 10.092026-06-05
Year to date+31.69%USD 9.752025-12-31
1 year-6.42%USD 13.722025-09-03
3 year+261.69%USD 3.552023-08-28
5 year+22.29%USD 10.502021-09-03
Since inception+307.05%USD 3.152019-09-04

Innovent Biologics Financials at a Glance

Market Cap

$22.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥26.89B

Net Income (TTM)

CN¥2.35B

EPS (TTM)

$0.10

P/E Ratio

123.34

Dividend

$0.00

Beta (Volatility)

0.05 (Low)

Price

$12.84

Volume

145

Open

$13.99

Previous Close

$12.84

Daily Range

$12.84 - $13.99

52-Week Range

$9.10 - $15.01

Estimated Earnings Date

Mar 31, 2027

IVBXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innovent Biologics

Innovent Biologics, Inc. is a biopharmaceutical firm based in Suzhou, China, established in 2011. The company specializes in the discovery, development, and production of antibody-based drug candidates, focusing on oncology, ophthalmology, immunology, and metabolic diseases.

Products and Services
  • Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for various cancers
  • Byvasda, targeting diverse malignant tumors
  • Halpryza, for non-Hodgkin's lymphoma and chronic lymphocytic leukemia
Growth Outlook
  • Strong pipeline with multiple investigational therapies in development
  • Strategic partnerships with major pharmaceutical companies enhance market reach
  • Increasing demand for innovative cancer therapies supports revenue growth
Financial Highlights
  • Recent quarterly revenue of 6.97 billion CNY, showing significant growth
  • TTM gross profit margin of 76.4%, indicating strong operational efficiency
  • Current ratio of 2.62, reflecting solid liquidity position
Innovent Biologics, Inc. has established itself as a key player in the biopharmaceutical industry, particularly in the oncology sector. The company's flagship product, Tyvyt, has gained traction in the market, contributing to its revenue growth. The robust pipeline of investigational therapies, including biosimilars and monoclonal antibodies, positions Innovent for future expansion. Strategic alliances with renowned partners further enhance its capabilities and market presence. Financially, the company demonstrates strong operational efficiency with a high gross profit margin and a solid liquidity position, making it an attractive option for potential investors interested in the biotechnology sector.
AI Generated • Aug 24, 2026

Industry

Biotechnology

Sector

Health Care

Employees

7,502

CEO

De Chao Yu, PhD

Website

www.innoventbio.com

Headquarters

Suzhou, JS 215123, CN

IVBXF Financials

Key Financial Metrics (TTM)

Gross Margin

80.96%

Operating Margin

12.02%

Net Income Margin

7.80%

Return on Equity

6.06%

Return on Capital

8.88%

Return on Assets

2.92%

Earnings Yield

0.81%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$22.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.74B

Volume

145

Avg. Volume

1.72K

Financials (TTM)

Gross Profit

CN¥22.04B

Operating Income

CN¥3.36B

EBITDA

CN¥4.05B

Operating Cash Flow

CN¥11.48B

Capital Expenditure

-CN¥596.92M

Free Cash Flow

CN¥10.88B

Cash & ST Invst.

CN¥20.00B

Total Debt

CN¥2.32B

Innovent Biologics Performance Analysis

Innovent Biologics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 676,651,8492.2%
20232023-12-31CNY 875,941,41829.5%
20242024-12-31CNY 1,309,174,21649.5%
20252025-12-31CNY 1,814,233,46038.6%
Innovent Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3138.4%
Q22025-06-308.8%
Q42025-12-3117.1%
Q22026-06-3021.9%
Innovent Biologics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.22-25.3%
20232023-12-31CNY -0.09-57.2%
20242024-12-31CNY -0.01-91.3%
20252025-12-31CNY 0.07N/A
Innovent Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31175.0%
Q22025-06-30172.2%
Q42025-12-31-105.0%
Q22026-06-302875.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥8.50B

+115.1%

Gross Profit

CN¥7.22B

+152.7%

Gross Margin

84.96%

N/A

Market Cap

$22.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.98M

N/A

Employees

7,502

N/A

Net Income

CN¥1.24B

+414.8%

EBITDA

CN¥2.21B

+987.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥20.00B

+131.8%

Total Debt

CN¥2.32B

-30.6%

Accounts Receivable

CN¥1.90B

+39.0%

Inventory

CN¥1.88B

+171.8%

Long Term Debt

CN¥1.78B

-23.7%

Short Term Debt

CN¥551.12M

-45.5%

Return on Assets

2.92%

N/A

Return on Invested Capital

5.80%

N/A

Free Cash Flow

CN¥0.00

+100.0%

Operating Cash Flow

CN¥0.00

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNMSFGenmab A/S
$338.00+0.00%
WXIBFWuXi Biologics (Cayman) Inc.
$6.23+0.00%
SUVPFSartorius AG
$270.29+0.00%
ALPMFAstellas Pharma Inc.
$14.81+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About IVBXF

What is the current price of Innovent Biologics?

Innovent Biologics is trading at $12.84 per share.

What is the 52-week range for Innovent Biologics?

Over the past 52 weeks, Innovent Biologics has traded between $9.10 and $15.01.

How much debt does Innovent Biologics have?

As of the most recent reporting period, Innovent Biologics reported total debt of CN¥402.94M.

How much cash does Innovent Biologics have on hand?

Innovent Biologics reported CN¥1.48B in cash and cash equivalents in its most recent financial results.

What is Innovent Biologics’s dividend yield?

Innovent Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services